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INTRODUCTION 
There is a significant person-to person variation in the degree of decline 
in physical performance and cognition in the elderly. A major factor accounting 
for this variability is the presence or absence of multiple chronic diseases like 
stroke, coronary artery disease, peripheral vascular diseases. 
Numerous studies have demonstrated the importance of dyslipidemia as 
a risk factor for such vascular events. However, most of these studies have 
considered only total serum cholesterol concentration. More recently, some 
authors have shown that other lipid variables like HDL-cholesterol, may play a 
role in predicting the risks of vascular disease. 
One of the most important mechanism by which HDL-cholesterol plays 
its atheroprotective function is the reverse cholesterol transport. Furthermore, 
HDL-cholesterol exerts direct nitric oxide-mediated vasodilatory effects. The 
capacity of HDL-cholesterol to enhance the activity of nitric oxide in the small 
arteries may have a role in the reduction of arterial inflammation at the place of 
atheroma formation. 
Being a negative predictor of vascular events, the effect of HDL-
cholesterol on physical performance and cognition in elderly has been studied 
in Europe and Central Asia – and a positive correlation found.   
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The studies done in this subject were mainly from Korea and China 
(Central Asia). We could not find any Indian studies. Hence the purpose of this 
study is to assess the effect of HDL cholesterol on physical performance and 
cognition in the Indian population .If a positive correlation is established, 
improved HDL-cholesterol levels by pharmacological intervention could get 
better physical performance and cognition in the aged. 
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AIMS AND OBJECTVES 
AIM 
• To study the effect of HDL on physical performance and 
cognition in elderly. 
• To analyze the association of HDL with co-morbidities. 
 
OBJECTIVES 
Persons attending geriatric OPD at Rajiv Gandhi Govt. General 
Hospital, are categorized into three tertiles based on HDL levels and 50 
patients from each group are selected by simple random sampling The physical 
performance and cognition of patients in each group is assessed through SPPB 
and MMSE score and the effect of HDL cholesterol on physical performance 
and cognition in elderly, studied. 
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REVIEW OF LITERATURE  
Lipoproteins are “large macromolecular complexes composed of lipids 
and proteins (apolipoproteins) that play an essential role in  
•  Absorption of dietary cholesterol, long chain fatty acids and fat soluble 
vitamins 
•  Transport of triglycerides, cholesterol and fat soluble vitamins from the 
liver to peripheral tissues and 
•  Transport of cholesterol from peripheral tissues to the liver and 
intestine.” 
The amount of lipid (which is less dense than water) determines the 
density of a lipoprotein. Based on their relative densities, lipoproteins are 
classified into five groups:   
• Chylomicrons 
• Very low density lipoprotein (VLDL) 
• Intermediate density lipoprotein (IDL) 
• Low density lipoprotein (LDL) 
• High density lipoprotein (HDL) 
 Chylomicrons, that are the most lipid rich, are the least dense 
lipoprotein particles; whereas HDLs that have the least lipid content are the 
most dense lipoproteins. 
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The proteins associated with lipoproteins called apolipoproteins are 
required for the assembly, structure, function and metabolism of lipoproteins. 
Apolipoproteins act as ligands for cell surface receptors and play an important 
role in the activation of enzymes involved in lipoprotein metabolism. 
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Types of  Apolipoproteins - 
ApoB is a very large protein and is the major structural protein of 
chylomicrons, VLDLs, IDLs and LDLs; one molecule of apoB-48 
(chylomicron) or apoB-100 (VLDL, IDL or LDL) is present on each 
lipoprotein particle. The apoB-48 is derived from the same gene as apoB-100 
by mRNA editing. While apoB-100 is synthesized in the human liver,  apoB-48 
is produced in the intestines.  
ApoA-1 is a different class of apolipoproteins, that is found virtually on 
all HDL particles. It is primarily synthesized in the liver and intestine. ApoA-2 
is the second most abundant HDL apolipoprotein and is found in approximately 
2/3rds of the HDL particles.  
ApoC-1, apoC-2 and apoC-3 participate in the metabolism of 
triglyceride rich lipoproteins. ApoE also plays a critical role in the metabolism 
and clearance of triglyceride rich particles. Most apolipoproteins, other than 
apoB, exchange actively among lipoprotein particles in the blood.  
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Transport of intestinally derived dietary lipids by 
chylomicrons 
 One of the key functions of lipoproteins is the efficient transport of 
dietary lipids from the intestines to the peripheral tissues. The triglycerides 
present in the diet are first hydrolyzed by lipases within the intestinal lumen 
and then emulsified with bile acids to form micelles. Likewise, dietary 
cholesterol is absorbed in the proximal small intestine and esterified to form 
cholesteryl esters. Longer chain fatty acids are incorporated into triglycerides 
and packaged with apoB-48, cholesteryl esters, phospholipids and cholesterol 
to form chylomicrons. The nascent chylomicrons are then secreted into the 
intestinal lymph and later reach the systemic circulation via the thoracic duct.  
CHYLOMICRON 
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In the systemic circulation the chylomicrons encounter lipoprotein 
lipase, attached to the endothelial surfaces of capillaries in adipose tissue, heart, 
and skeletal muscle. The triglyceride of chylomicrons are hydrolyzed by 
lipoprotein lipase (LPL) and free fatty acids are released. ApoC-2 which is 
transferred to circulating chylomicrons from HDL, acts as a required co factor 
for LPL in this reaction. The released free fatty acids are taken up by the 
adjacent myocytes or adipocytes and are either oxidized to generate energy or 
re-esterified and stored as triglyceride. As the process gets repeated (hydrolysis 
of the hydrophobic core) the chylomicron particles progressively shrink in size, 
creating chylomicrons remnants. 
Chylomicron remnants are rapidly removed from the circulation by the 
liver through a process that requires apoE as a ligand for receptors in the liver. 
Consequently, few, if any, chylomicrons or chylomicron remnants are 
generally present in the blood after 12hr-fast, except in patients with certain 
disorders of lipoprotein metabolism. 
Transport of hepatically derived lipids by VLDL and LDL 
Another key role of lipoproteins is the transport of hepatic lipids from 
the liver to the periphery. VLDL resemble chylomicrons in protein composition 
except that they contain apoB-100 rather than apoB-48 and have a higher ratio 
of cholesterol to triglyceride. After secretion into the plasma, VLDL acquires 
multiple copies of apolipoproteins of C and E series by transfer from HDL. As 
with chylomicrons the triglycerides of VLDL are hydrolyzed by LPL, 
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especially in muscle, heart and adipose tissue. After the VLDL remnants 
dissociate from LPL, they are referred to as IDLs and they contain roughly the 
same amounts of cholesterol and triglycerides. The liver removes 
approximately 40-60% of IDL by LDL receptor mediated endocytosis via 
binding to apoE. The remainder of IDL is remodeled by hepatic lipase to form 
LDL (during the process of remodeling phospholipids and triglycerides in the 
particle are hydrolyzed, and all lipoproteins except apoB-100 are transferred to 
other lipoproteins). Approximately 70% of LDL is removed from the 
circulation by the liver in a similar manner as IDL; however in this case apoB  
binds with the LDL receptor, rather than apoE. 
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HDL metabolism and reverse cholesterol transport 
Though all nucleated cells can synthesize cholesterol, only hepatocytes 
and enterocytes can effectively excrete cholesterol from the body- into either 
the bile or the gut lumen. In the liver cholesterol is secreted into the bile either 
directly or after conversion into bile acids. Cholesterol in peripheral cells is 
transported to the liver and intestine by a process termed reverse cholesterol 
transport, that is facilitated by HDL. 
Nascent HDL particles are synthesized by the liver and intestines. 
Newly secreted apoA-1 rapidly acquires phospholipids and unesterified 
cholesterol from its site of synthesis via efflux promoted by the membrane 
protein ATP binding cassette protein A1 (ABCA1). This process results in the 
formation of discoidal HDL particles, which then recruit additional unesterified 
cholesterol from cells or circulating lipoproteins. Within the HDL particle, the 
cholesterol is esterified by lecithin cholesterol acyl transferase ( a plasma 
enzyme associated with HDL) and the more hydrophobic cholesteryl ester 
moves to the core of the HDL particle. As HDL acquires more cholesteryl 
esters, it becomes spherical and additional apolipoproteins and lipids are 
transferred to the particles from the surfaces of chylomicrons and VLDLs 
during lipolysis.  
HDL cholesterol is transported to hepatocytes by both an indirect and a 
direct pathway. HDL cholesteryl esters can be transferred to apoB containing 
lipoproteins in exchange for triglycerides by the cholesteryl ester transfer 
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protein. The cholesteryl esters are then removed from the circulation by LDL 
receptor mediated endocytosis. HDL cholesterol can also be taken up directly 
by hepatocytes via the scavenger receptor class B1, a surface receptor that 
mediates the selective transfer of lipid to cells. 
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FUNCTIONS OF HDL CHOLESTEROL 
1.Cellular cholesterol efflux 
 HDL particles remove cholesterol from the cells of the arterial wall, 
primarily macrophages and macrophage-derived foam cells. This cholesterol 
efflux is responsible for the clinically relevant atheroprotective effect of HDL 
that forms the basis of the association between circulating levels of HDL-C and 
cardiovascular risk(1). Indeed, studies have shown that reduction of plasma 
HDL-C concentration may accelerate the development of atherosclerosis by 
impairing the clearance of cholesterol from the arterial wall.(2) 
2. Vasodilatory actions 
  Apart from playing a key role in cholesterol efflux, HDL has other 
anti-atherogenic properties. The beneficial effect of HDL on the endothelium 
includes the primary vasodilatory property, which is attributed to its capacity to 
stimulate NO release by endothelial cells (3) and increase NO bioavailability. 
Activation of NO production by HDL involves binding of the HDL 
particles to SR-BI as an initiating event (4). HDL bound to the extracellular 
loop of SR-BI initiates signaling in the endothelium that ultimately results in 
the activation of endothelial nitric oxide synthase (eNOS).(5) 
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Another pathway participating in vasodilatory effects of HDL in 
endothelial cells is mediated by ABCG1 and involves efflux of cholesterol and 
7-oxysterols which improves the formation of active eNOS dimers and results 
in decreased ROS production. Diminished cellular production of superoxide, 
which inactivates NO, can also increase in NO bioavailability and improved 
vasodilation in the presence of HDL.(6) 
Vasodilatory activity of HDL may translate into improved endothelial 
function; clinical evidence to support this hypothesis is accumulating. 
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3. Cytoprotective action 
HDL particles possess several cytoprotective properties.  
HDL protects both macrophages and endothelial cells from apoptosis 
induced by loading with free cholesterol or by oxidized LDL.  HDL-mediated 
protection from apoptosis induced by loading with free cholesterol or oxidized 
LDL is mediated by cellular efflux of oxidized cholesterols, primarily of 7-
ketosterol (7) . Cytoprotection is also related to intracellular antioxidative 
actions of HDL, which include reduced cellular generation of superoxide anion 
and/or hydrogen peroxide secondary to down-regulation of superoxide 
production by NADPH oxidase and/or mitochondrial electron transport 
chain.(8) 
Another cytoprotective activity of HDL relevant for vasoprotection 
involves inhibition of apoptosis, cell detachment, and extracellular matrix 
degradation induced by elastase in human vascular smooth muscle cells. Such 
an anti-elastase action can be related to the presence in HDL of serpin 
peptidase inhibitors, including alpha-1-antitrypsin.(9) 
4. Anti-inflammatory and anti-oxidative actions 
   HDL particles display multiple anti-inflammatory actions which 
collectively contribute to suppression of a chronic inflammatory response in the 
arterial wall which evolves in response to LDL-derived cholesterol deposition 
(10). HDL potently decreases adhesion molecule expression on endothelial 
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cells activated by cytokines and thereby inhibits monocyte adhesion to the 
endothelium both in vitro and in vivo. HDL also directly inhibits monocyte 
activation, reducing expression of chemokines and chemokine receptors via the 
modulation of nuclear factor kappa B (NFkB) and PPAR gamma.  
HDL particles also inhibit stimulation of T-cells by antigen-presenting 
cells and activation of monocytes by stimulated T-cells, thereby inhibiting the 
production of proinflammatory cytokines and chemokines induced by T-cell 
contact with monocytes. Interaction of HDL with T-lymphocytes, which blocks 
subsequent activation of monocytes by lymphocytes, can account for this 
effect. HDL can also restore the emigratory process of macrophages and 
monocyte-derived dendritic cells and thus result in the resolution of 
inflammatory reactions in atherosclerotic plaques In addition, HDL potently 
reduces neutrophil activation in vivo and in vitro. Collectively, these effects 
constitute an important facet of HDL action on the innate and adaptive 
immunity. 
The multiple effects of HDL on the immune system suggest that several 
mechanisms of action may be operative. Cellular efflux of non-oxidized and 
oxidized lipids may form a mechanistic basis for the capacity of HDL to 
decrease adhesion molecule expression, for direct inhibitory actions of HDL on 
monocyte and neutrophil activation, and for reductions in myeloid cell 
proliferation and monocytosis. 
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Antioxidative properties of HDL are closely linked to its anti-
inflammatory potential. Indeed, oxidative modifications of cholesterol-rich 
lipoproteins, primarily LDL, retained in the arterial wall result in the formation 
of highly pro inflammatory oxidized phospholipids, such as 1-palmytoyl-2-(5-
oxovaleroyl)-sn-glycero-3-phosphocholine and 1-palmitoyl-2-glutaroyl-sn-
glycero-3-phosphocholine. The response-to-retention hypothesis of 
atherosclerosis postulates that these and other products of LDL oxidation, 
acting together, induce local inflammatory response. HDL-mediated protection 
of LDL from pathological oxidation may therefore result in the inhibition of 
inflammation. 
HDL can protect LDL and other lipoproteins from oxidative stress in 
vitro induced by various oxidants, which include one- and two-electron species. 
Removal of oxidized lipids from LDL or cells represents the first step of HDL-
mediated protection from oxidative damage induced by free radicals. Indeed, 
phospholipid hydroperoxides (PLOOHs) are rapidly transferred from oxidized 
LDL to HDL upon their co-incubation.  
Inactivation of oxidized lipids associated with HDL particles represents 
the second step in this antioxidative pathway. Depending on their structure, 
oxidized lipids can be reduced (LOOHs) by apoA-I and other redox-active 
HDL components or hydrolysed (short-chain oxidized phospholipids, 
lysophosphatidylcholine) by HDL-associated hydrolytic enzymes. 
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As a consequence, HDL particles constitute a major transport vehicle of 
LOOH in human plasma and may therefore function as a ‘sink’ for oxidized 
lipids which can accumulate in the particle when the LOOH-inactivating 
capacity of HDL is overwhelmed. Subsequently, CEOOHs and their 
corresponding hydroxides can be rapidly removed from HDL via selective 
uptake by the liver mediated by SR-BI. 
HDL also inhibits generation of reactive oxygen species (ROS) and 
decreases intracellular oxidative stress both in vitro and in vivo. Such 
antioxidative actions of HDL require interaction with surface receptors, 
including SR-BI and ABCG1, but do not necessitate direct contact between 
HDL and prooxidative agents in the extracellular compartment. Diminished 
cellular production of superoxide and/or hydrogen peroxide may be implicated 
in the antioxidative effect of HDL in endothelial cells. 
5. Protection from infection 
   Plasma HDL displays several anti-infectious activities which may 
contribute to the innate immunity. Indeed, HDL binds circulating LPS and 
participates in its hepatic clearance to the bile, thereby inhibiting LPS-induced 
cellular activation and endotoxic shock in animal models.(10) 
Furthermore, human plasma HDL is a major carrier of specific 
trypanosome lytic activity, which selectively protects humans 
from Trypanosoma brucei brucei, a parasitic species that causes sleeping 
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sickness. Trypanosome lytic factor constitutes a minor subpopulation of HDL 
particles, which is characterized by the ability to kill T.b. brucei. HDL-
mediated killing of T. b. brucei occurs through a unique mechanism of ionic 
pore formation in endosomal membranes of the parasite.(11) 
6. Modulation of glucose metabolism 
  Human plasma HDL efficiently improves glucose metabolism by 
multiple mechanisms (12) (13) which include enhanced insulin secretion by 
pancreatic beta-cells, improved insulin sensitivity and maintenance of 
cholesterol homeostasis. Indeed, infusions of reconstituted HDL reduce plasma 
glucose and increase plasma insulin when compared with placebo in patients 
with Type 2 diabetes. In vitro HDL accelerates insulin secretion beta-cells via a 
mechanism that involves removal of excess cholesterol through ABCA1 
(14). Another pathway contributing to improved insulin sensitivity under the 
action of HDL includes protection of pancreatic beta-cells from apoptosis. 
Activation of intracellular survival pathways, which underlies this effect, 
involves altered expression of inducible nitric oxide synthase, Fas, and FLICE-
like inhibitory protein (FLIP). 
HDL equally improves insulin sensitivity at the level of skeletal muscle 
(15). Specifically, HDL activates the AMPK pathway via elevated 
phosphorylation of acetyl-CoA carboxylase 2 (ACC-beta) and increases 
glucose uptake by cultured skeletal muscle cells. This effect involves binding to 
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ABCA1 and activation of calcium/calmodulin-dependent protein kinase 
kinase.   
 
 
7. Reduction of platelet activation 
   HDL exerts several anti-thrombotic effects which primarily include 
reduction of platelet activity (16). In vitro anti-thrombotic activities of HDL are 
expressed as dose-dependent inhibitory actions on agonist-stimulated platelet 
aggregation, fibrinogen binding, granule secretion, and thromboxane A2 and 
12-hydroxy-eicosatetraenoic acid production (17). HDL decreases platelet 
aggregation mediated by glycoprotein IIb/IIIa in response to thrombin, 
collagen, ADP, and adrenaline. (18) 
The above action is brought about by the following mechanism. 
Interaction of HDL with the platelet SR-BI receptor may trigger intracellular 
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signaling cascades, which encompass intracellular release of diacylglycerol 
from plasma membrane phosphatidylcholine, activation of protein kinase C, 
stimulation of the Na+/H+ antiport, alkalization of the cytoplasm, and inhibition 
of calcium release from storage sites (19). 
In addition to its effects on platelets, HDL exerts anti-thrombotic effects 
on endothelial cells. The anti-thrombotic effects of HDL towards endothelial 
cells depends on the stimulation of cellular NO production, which is in turn 
triggered by the interaction of HDL with platelet SR-BI. 
Apart from this HDL may also inhibit factors which promote blood 
coagulation, including tissue factor and factors X, Va, and VIIIa (20). 
9. Regulation of gene expression by miRs 
Recently, HDL has been shown to transport small non-coding miRs. 
Multiple copies of several miRs are transported by circulating HDL in 
man. miRs are key intracellular regulators of gene expression which post-
transcriptionally control cellular cholesterol homeostasis, including cholesterol 
efflux. HDL carries miRs that control cholesterol metabolism; miR-33 down-
regulates expression of ABCA1 and ABCG1 and reduces HDL biogenesis in 
mice (21). As a corollary, both antagonism and deficiency of miR-33 raise 
circulating HDL-C levels, enhance macrophage cholesterol efflux, and prevents 
progression of atherosclerosis. Such anti-atherosclerotic effects suggest 
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antagonism and down-regulation of miR-33 as a novel strategy for 
atheroprotection. 
10. Cholesterol handling in the brain 
  Brain relies heavily on cholesterol supply which is essential for cell 
membrane synthesis and myelin production. Strikingly, while the central 
nervous system accounts for only 2.1% of body weight, it contains 23% of the 
whole body cholesterol pool. Cholesterol transport mediated by lipoproteins 
has long been thought to underlie the proper functioning of the brain. Indeed, 
all major types of neuronal cells can bind and internalize lipoproteins present in 
the extracellular fluid. 
Brain lipoproteins appear to be similar to those of cerebrospinal fluid, as 
a consequence of the passage between the two compartments.  
Human cerebrospinal fluid primarily contains spherical lipoproteins of 
approximately 10–22 nm in diameter with a density of 1.063–1.25 g/mL, which 
corresponds to the density of HDL and very-HDL of human plasma (22). 
Lipoprotein concentrations in the cerebrospinal fluid are, however, several 
hundred-fold lower when compared with the plasma compartment. 
 ApoE and apoA-I are the major apolipoproteins in human CSF, with 
slightly higher concentration of the former. ApoE- and cholesterol-rich 
lipoproteins secreted by astrocytes appear to ensure a continuous supply of 
cholesterol required for normal functioning of neurons (23). 
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 In addition, HDL obtained from cerebrospinal fluid efficiently effluxes 
cholesterol from neuronal cells. Similar to the plasma compartment, 
metabolism of brain lipoproteins is regulated by ABCA1, ABCG1 and other 
proteins known to participate in plasma lipoprotein metabolism. Available data 
indicate that metabolism of brain lipoproteins can be impaired in Alzheimer's 
disease, as occurs in the presence of apolipoprotein E4, the primary genetic risk 
factor for the sporadic disease (24). 
 
FACTORS INFLUENCING HDL LEVELS(25) 
EXERCISE 
It has been established that regular aerobic exercise increases the HDL 
cholesterol level by 3 to 9 percent in healthy individuals, irrespective of the age 
group. This increase is linked to the frequency and intensity of physical 
activity. It is expected that with frequent, low-intensity exercise (e.g., five 30-
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minute sessions per week vs. three 60-minute sessions) there would be greater 
increase in HDL cholesterol .However, there is little evidence that walking 
significantly increases HDL cholesterol levels. HDL cholesterol levels may 
increase with as little as eight weeks of regular exercise, although changes may 
not be evident for two years. Exercise may increase HDL cholesterol levels by 
stimulating the production of pre beta HDL cholesterol and reverse cholesterol 
transport. Regular exercise yields a greater increase in HDL cholesterol in men 
with low HDL cholesterol levels, elevated triglyceride levels, and abdominal 
obesity than in those with isolated low HDL cholesterol levels. 
Weight loss may be crucial for an increase in HDL cholesterol to occur. 
In one randomized, controlled trial, persons who walked or jogged 10 miles per 
week but did not lose weight did not have different HDL cholesterol levels 
from those of controls. Nevertheless, it is reasonable to recommend a program 
of regular, brisk aerobic exercise for 30 minutes on most days of the week. 
SMOKING CESSATION 
 Cigarette smoking is associated with reduced HDL cholesterol, 
lecithin–cholesterol acyltransferase activity and cholesteryl-ester–transfer 
protein (CETP) activity. 
After smoking cessation, HDL cholesterol increases (by a mean of 4 mg 
per deciliter [0.10 mmol per liter]), more so in women than in men and in 
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persons with elevated baseline HDL cholesterol levels (>47 mg per deciliter 
[1.21 mmol per liter]). 
 It is necessary to recommend a comprehensive approach (involving 
pharmacotherapy, nicotine replacement, and counseling) for smoking cessation. 
WEIGHT CONTROL 
 Reduced HDL cholesterol levels and elevated serum triglyceride levels 
are associated with obesity. A negative correlation exists between HDL 
cholesterol and body-mass index. A meta-analysis examining the effect of 
weight loss on HDL cholesterol levels demonstrated that the levels increased 
by 0.35 mg per deciliter (0.009 mmol per liter) per kilogram of weight 
reduction in subjects who achieved a stabilized, reduced weight (P≤0.01) but 
decreased by 0.27 mg per deciliter (0.006 mmol per liter) in subjects during 
active weight loss (P≤0.05).In subjects who maintained a stable weight for six 
weeks after weight loss, HDL cholesterol levels, lipoprotein lipase levels, and 
lecithin– cholesterol acyltransferase activity increased; these increases may 
contribute to enhanced cholesterol esterification and reverse cholesterol 
transport. A reasonable weight-loss goal for overweight or obese patients is 1 
lb (0.45 kg) per week, with a target body-mass index of less than 25. 
ALCOHOL INTAKE 
 Moderate alcohol consumption raises HDL cholesterol levels. A meta-
analysis indicated that the consumption of 30 g (1 fluid oz) of alcohol per day 
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increases HDL cholesterol levels by a mean of 4 mg per deciliter. This has 
been observed irrespective of the kind of alcohol consumed. Persons who 
consume one to three drinks daily have higher HDL cholesterol levels and a 
lower risk of myocardial infarction than do those who drink less, even after 
adjustment for other likely confounding factors. Thus, for many persons with 
low HDL mild-to-moderate alcohol consumption (no more than one to two 
drinks per day) appears to be reasonable. However, the potential risks 
associated with this recommendation may outweigh the benefits in persons 
with hepatic dysfunction or the potential for addiction. Alcohol consumption 
may elevate HDL cholesterol levels by increasing cellular cholesterol efflux 
and plasma cholesterol esterification. 
DIETARY FAT INTAKE 
 Reduction in the intake of dietary fat leads to decline in plasma LDL 
and HDL levels. In a study comparing calorically balanced diets (i.e., intake is 
equal to expenditure) that differed in fat content, subjects who consumed a 
low-fat diet (19 percent of total calories were from fat) had lower HDL 
cholesterol and apolipoprotein A-I levels than did subjects who were fed a 
high-fat diet (50 percent of total calories were from fat) (54 mg per deciliter 
[1.40 mmol per liter] vs. 63 mg per deciliter [1.63 mmol per liter] and 118 mg 
per deciliter [3.05 mmol per liter] vs. 127 mg per deciliter [3.28 mmol per 
liter], respectively; P<0.005). The concomitant decrease in LDL cholesterol 
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that occurs with a diet low in saturated fat may override the effects associated 
with the decline in HDL cholesterol. 
Native Alaskan population that eat a diet rich in n–3 polyunsaturated 
fatty acids have high HDL cholesterol levels. Although a diet high in 
monounsaturated fats does not elicit a significant change in HDL cholesterol 
levels, the dietary glycemic load (which represents the equivalent elevating 
effect on blood-glucose levels of 1 g of pure glucose or white bread) is 
negatively correlated with HDL cholesterol levels. Thus, a diet rich in n–3 
polyunsaturated fatty acids — sources include oils (olive, canola, soy, 
flaxseed), nuts (almonds, peanuts, walnuts, pecans), cold-water fish (salmon, 
mackerel), and shellfish — with limited carbohydrates can be recommended to 
increase serum HDL cholesterol levels. 
LIFESTYLE AND MODIFYING FACTORS 
 Improvement in HDL cholesterol levels associated with exercise, 
moderate alcohol consumption, and weight loss is greatest in persons with the 
highest baseline HDL cholesterol levels (60 mg per deciliter [1.55 mmol per 
liter] or more); those with low baseline levels have less improvement.  
The magnitude of improvement in HDL cholesterol levels associated 
with lifestyle modifications is influenzed by the interactions between genes and 
the environment. Specifically, improvement with exercise may depend on 
individual CETP and endothelial lipase genotypes. However, genetic tests for 
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these factors are not currently used in routine practice, and lifestyle changes as 
described above should be recommended routinely, both to raise HDL 
cholesterol levels and to lower LDL cholesterol levels and improve other 
cardiovascular risk factors. 
MEDICATION 
 Several classes of medications increase HDL cholesterol levels; these 
include niacin and fibrates, in particular, and, to a lesser degree, statins. These 
medications also lower triglycerides and LDL cholesterol levels. Without trials 
designed to isolate the effects of drugs on changes in HDL cholesterol levels 
and on coronary outcomes, it is difficult to determine how much of the drugs’ 
benefit in reducing the rates of coronary heart disease are due to changes in 
HDL cholesterol levels. At present, there is no clear consensus regarding when 
to use medications for the purpose of raising HDL cholesterol levels, although 
drugs are most often considered for patients with established coronary disease 
or for those at high risk. 
NIACIN 
 Niacin (nicotinic acid or vitamin B 3) is the most effective medication 
to raise HDL cholesterol levels, causing increases of 20 to 35 percent. The 
Coronary Drug Project demonstrated a significant reduction in the incidence of 
death and myocardial infarction after five years of niacin treatment among men 
with a history of myocardial infarction.  
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Niacin inhibits hepatic uptake of apolipoprotein A-I and increases 
plasma pre beta HDL cholesterol levels. Niacin therapy is associated with 
improved endothelial function and nitric oxide synthase activity.  
The side effects of niacin therapy include cutaneous flushing, dyspepsia, 
and elevation of plasma glucose and uric acid levels. Flushing, which is largely 
mediated by prostaglandins, may be minimized with the use of an extended-
release formulation of niacin (not the same as sustained-release niacin); with 
the concurrent consumption of a low fat snack at bedtime, 30 minutes after 
ingestion of an aspirin; and with a regimen that begins with a low dose (e.g., 
500 mg each night) and increases gradually. 
FIBRATES 
 Fibrate therapy results in an increase in HDL cholesterol levels of 10 to 
25 percent. This is brought about by activating peroxisome-proliferator–
activated receptor A (PPARa), which in turn results in increased expression of 
the hepatic apolipoprotein A-I gene. 
 The Helsinki Heart Study and the Veterans Affairs High-Density 
Lipoprotein Cholesterol Intervention Trial demonstrated increases in HDL 
cholesterol (10 percent and 6 percent, respectively) and a large reduction in 
triglyceride levels in asymptomatic men and those with primary dyslipidemia 
or coronary heart disease, respectively, who had been randomly assigned to 
receive gemfibrozil (1200 mg daily), as compared with subjects who received 
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placebo. Gemfibrozil significantly reduced the risks of coronary   events (34 
percent) and the combined outcome of coronary death, nonfatal myocardial 
infarction, and stroke (24 percent). 
 Subsequent analysis of the Veterans Affairs trial indicated that only the 
increase in HDL cholesterol levels, not the change in LDL cholesterol or 
triglyceride levels, significantly predicted a reduced risk of coronary events. 
STATINS  
 In addition to lowering LDL cholesterol levels, statins raise HDL 
cholesterol levels by 2 to 15 percent by increasing apolipoprotein A-I synthesis. 
 In a randomized trial comparing the effects of simvastatin and 
atorvastatin (maximum dose, 80 mg and 40 mg, respectively, titrated to LDL 
cholesterol levels) among patients with elevated LDL cholesterol levels, there 
was a moderately greater increase with simvastatin in HDL cholesterol levels 
(9 percent vs. 7 percent, P<0.001) and apolipoprotein A-I levels (6 percent vs. 
3 percent, P<0.001); clinical outcomes were not assessed. Several trials have 
documented reduced risks of major coronary events associated with the use of a 
statin, as compared with placebo, but it is not clear whether the rise in HDL 
cholesterol levels is an independent predictor of the reduced risk of coronary 
events with the use of these agents. 
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COMBINATION THERAPY 
In some patients with low HDL cholesterol levels, various lipid-
modifying medications may be useful in combination. The HDL 
Atherosclerosis Treatment Study (HATS) demonstrated that a combination of 
low-dose simvastatin (10 to 20 mg per day) and high-dose niacin (2 to 4 mg per 
day) significantly increased HDL cholesterol levels (26 percent), as compared 
with placebo, in patients with HDL cholesterol levels of 40 mg per deciliter or 
less, LDL cholesterol levels of 145 mg per deciliter (3.75 mmol per liter) or 
less, and triglyceride levels of less than 400 mg per deciliter (4.52 mmol per 
liter). In the simvastatin–niacin treatment group, coronary stenosis, as 
documented on angiography, moderately regressed over three years (0.4 
percent, P<0.001 vs. placebo; 3.9 percent increase). The Arterial Biology for 
the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 
2 study, which involved subjects who had established coronary disease, HDL 
cholesterol levels of less than 45 mg per deciliter (1.16 mmol per liter), and 
LDL cholesterol levels of less than 130 mg per deciliter (3.36 mmol per liter), 
showed that the addition of extended-release niacin (1000 mg daily) to existing 
statin therapy increased mean HDL cholesterol levels by 21 percent (from a 
mean of 39 to 47 mg per deciliter [1.01 to 1.21 mmol per liter]; P<0.001 vs. the 
change in the placebo group). Medial thickness of the carotid intima 
significantly increased in the placebo group (mean change, 0.044 mm; 
P<0.001) but not in the placebo group (mean change, 0.014 mm; P=0.23); 
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however, a comparison of changes in intimal thickness over time did not show 
a significant difference between the two groups (P=0.08). 
HDL CHOLESTEROL IN ELDERLY 
Worldwide the percentage and absolute number of elderly individuals 
are greater than ever before. With no historical example of such large and 
rapidly growing cohorts of older adults, the world is entering uncharted waters. 
Since 1950s, the number of older people as a share of the global population has 
increased very gradually, but projections indicate much sharper increase in the 
coming decades.  
The United Nations population Division   projects an increase in the 
number of individuals aged 60+ from about 901 million today (12% of the 
world population) to 2.1 billion by 2050 (21.5%).The number of oldest old 
individuals, defined as those aged 80+, is projected to triple from 125 million 
today (2% of the world population) to 434 million (4.5%) by 2050. 
Population ageing (the dominant demographic trend of this century) and 
the burden of non-communicable diseases will usher in challenges in several 
areas. Thus proactive responses are needed to mitigate the burden posed by the 
greying society. 
A long and healthy life is universally valued. However there is a 
considerable variation in the markers of ageing and age related diseases 
between individuals of a similar age. The starkest inequalities in later life are 
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how many years of life remain at an older age such as 65+ and how many years 
of that life remain free from disabilities that impede physical and cognitive 
functioning to the extent that they limit the sense of valuing one’s life.  
Several factors influence mental and physical sustainability in later life- 
birth weight, education, socioeconomic position and lifestyle (diet, physical 
activity, smoking) etc. The influence of modifiable factors on ageing has been 
under study in the recent years. Dyslipidemia is one among them. 
The atheroprotective effect of HDL, through its reverse cholesterol 
transport, is well established. Therefore, having low HDL cholesterol 
concentration predisposes people to atherosclerotic disease and stroke, 
peripheral vascular disease, lower-extremity amputation, and loss of kidney 
function, which in turn impair physical performance.  
 HDL cholesterol not only improves physical performance but also is 
probably related to preserving the cognitive function, by preventing the 
formation of amyloid-beta in senile plaques, which constitutes one of the 
defining hallmarks of Alzheimer's disease (Olesen&Dagø, 2000).  
This association of HDL with physical performance and cognition has 
been evaluated in several studies. To quote a few, 
• In the ilSIRENTE study (26), conducted in Central Italy, 
the relationship of HDL-cholesterol with physical performance in 
community dwelling older persons aged 80 years and above was studied. 
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The participants of the study were grouped into three tertiles based on 
their HDL levels. The parameters like physical performance (SPPB), 
muscle strength (hand grip), functional status (IADL) and blood 
measurements (serum albumin, cholesterol (HDL and LDL), C-reactive 
protein and urea) were assessed in each group and a comparison was 
drawn. Compared with the participants with the first tertile of HDL-
cholesterol, those in the third tertile were younger, more likely to be 
women and had a higher prevalence of osteoarthritis. On the contrary, 
subjects in the third tertile of HDL-cholesterol had a lower prevalence of 
congestive heart failure, diabetes and cerebrovascular diseases, and 
tended to be more physically active, compared with the other 
participants. Albumin, urea and LDL-cholesterol increased as HDL 
cholesterol increased, while C-reactive protein declined with increasing 
HDL-cholesterol tertiles.  
In the unadjusted analysis physical function (as measured by the 
4-m walking speed, the SPPB score, the Basic and IADL scales scores), 
but not hand-grip strength, improved significantly as HDL-cholesterol 
tertiles increased. After adjustment for potential confounders, which 
included age, gender, living alone, alcohol abuse, physical activity, 
congestive heart failure, diabetes, cerebrovascular diseases, 
osteoarthritis, albumin, urea, C-reactive protein, and LDL cholesterol, 
the association of HDL-cholesterol tertiles with the 4-m walking speed 
and the SPPB score was still consistent. The results showed that, in 
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older persons, physical function declines as serum HDL-cholesterol 
levels decline. This association was consistent in very old participants 
and in both gender groups. 
 
• In a study published in Japan Geriatrics Society in 2011 
(27), the association between HDL-C levels and physical and cognitive 
performance was analyzed. Functional status was determined by the 
Lawton–Brody Index (LI) for instrumental activities of daily living 
(IADL) and the Barthel Index (BI) for basic activities 
(BADL).Cognition was assessed using the Spanish version of the Mini-
Mental State Examination (MMSE). As per the study results, normal 
HDL-C levels at baseline were significantly associated with higher BI 
scores (P < 0.006) and a lower number of prescription drugs used (P < 
0.04). However there was no significant association between HDL levels 
and MMSE.  
 
• In a study published in the Archives of Gerontology and 
Geriatrics 71 (28) the association between HDL cholesterol and 
functional state in the elderly Korean population was studied. Herein, 
elevated HDL cholesterol concentration was found to be strongly 
associated with higher MMSE score, ADL scale, and Chair RiseTest 
speed. 
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• Yet another study was conducted among Chinese 
elderly(29) to investigate the association of cholesterol level with 
cognitive performance. A total of 2000 elderly aged 65 years and over 
participated in this study. Total cholesterol (TC), triglycerides (TG), 
low density lipoprotein cholesterol (LDL-C) and high density 
lipoprotein cholesterol (HDL-C) concentration were determined and 
cognitive impairment was defined as Mini-Mental State Examination 
(MMSE) score≤23.The results of the study showed a significant 
positive linear association between cholesterol levels and MMSE score 
in linear regression models. These findings suggest that cholesterol 
levels within the high normal range are associated with better 
cognitive performance in Chinese elderly, specifically in the oldest 
old. With further validation, low cholesterol may serve a clinical 
indicator of risk for cognitive impairment in the elderly.   
• CSI-MCI study, conducted in China in 2016 (30), was a 
preliminary case-control study of the association of plasma 
lipids/lipoproteins with MCI in 112 MCI cases and 115 cognitively 
normal controls. Plasma total cholesterol (TC), high-density lipoprotein 
cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C),  
and triglycerides (TG) levels were measured in fasting blood samples. 
Multivariable logistic regression was used to evaluate the potential 
association between MCI and these factors. Statistical models were 
adjusted for multiple demographic and biological covariates. The results 
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of this study showed that plasma HDL level was significantly negatively 
associated with the risk of MCI. There was no association between 
plasma LDL level and the risk of MCI, adjustment for demographics, 
vascular disorders did not change this relation. 
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               MATERIALS AND METHODS 
STUDY CENTRE:   
Geriatric Medicine OPD & ward (male & female),   
Rajiv Gandhi Government General Hospital, Chennai- 3.   
ETHICAL COMMITTEE  APPROVAL:   
Approved by the Institutional Ethical Committee of Madras Medical 
College, Chennai   
STUDY DESIGN  :    
Cross sectional observational study (hospital based)   
PERIOD OF STUDY  :   
1year (August 2017- July 2018)   
SAMPLE SIZE   :   
150 patients   
INCLUSION CRITERIA  :   
Persons aged above 60 years willing to consent for the study  
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EXCLUSION CRITERIA :  
               
 
 
 
 
 
 
 
 
 
                               
 
 
          
Critically ill patients like advanced cardiac failure, stage 4,5 CKD.  
Acute stroke and previous stroke with major residual deficits. 
Patients with severe OA knee unable to perform SPPB 
Patients unable to comprehend simple instructions. 
Patients not willing to consent for the study. 
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DETAILS OF THE STUDY 
  
As per the above mentioned inclusion and exclusion criteria, people 
aged 60 years and above attending Geriatric medicine OPD of Rajiv Gandhi 
Govt. General Hospital, Chennai were selected by Simple random sampling. 
After getting informed written consent from all the study participants, basic 
information such as name, age, gender, educational status and contact details 
were obtained. Then history regarding the presence of comorbid illnesses like 
hypertension, diabetes mellitus, COPD/bronchial asthma, CAD, CVA was 
collected. Their habitual history like smoking and alcohol intake were also 
made note of.  
Then anthropometric measures like height, weight and BMI were 
calculated for the subjects and blood samples obtained for lipid profile. 
 Based on the HDL levels patients were stratified into three tertiles 
(<40mg/dl; 40-49mg/dl; >49mg/dl). The physical performance and cognitive 
function of subjects in each group was assessed using short physical 
performance battery score (SPPB) and mini mental status examination 
(MMSE) respectively. 
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SHORT PHYSICAL PERFORMANCE BATTERY (SPPB)  
The short physical performance battery (SPPB) is a group of measures 
that combines the results of the gait speed, chair stand and balance tests 
(Guralnik et al., 2000). It has been used as a predictive tool for possible 
disability and can aid in the monitoring of functional status in older people. The 
scores range from 0 (worst performance) to 12 (best performance). The SPPB 
has been shown to have predictive validity showing a gradient of risk for 
mortality, nursing home admission, and disability. 
Equipments Required 
Chair with arms  
Stopwatch 
Measuring tape 
 
Procedure 
1.REPEATED CHAIR STANDS 
Explain “I want to see how long it takes for you to stand up and sit down 
as quickly as possible 5 times without stopping. After standing up each time, sit 
down and then stand up again. Keep your arms folded across your chest. Please 
watch while I demonstrate. I’ll be timing you with a stopwatch” 
DEMONSTRATE TO THE PATIENT. 
Ask the participant if they are ready. If so, begin timing as soon as they 
bend forward at the hips. Count out loud the number of sits the participant has 
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performed. Stop the stop watch when they have sat down having completed the 
5th stand. Also stop if the participant starts to use their arms, or after 1 minute 
they have not completed the test. Stop if the participant cannot complete 5 
rises, and if you are concerned about the participant’s safety. Record the 
number of seconds and the presence of imbalance.  
Scoring the Repeated Chair Test 
Unable to complete 5 chair stands or    
Completes stands in >60 sec             :   ❒0 points 
Chair stand time - 16.70 sec or more:   ❒1 points 
Chair stand time - 13.70 to 16.69 sec : ❒2 points 
Chair stand time - 11.20 to 13.69 sec:  ❒3 points 
Chair stand time - 11.19 sec or less:    ❒4 points 
2. BALANCE TESTING  
           Explain “We will now look at your standing balance. We want to 
know if you can stand unsupported for 10 seconds with your feet in a certain 
position”. 
Explain “Begin with feet together beside each other. I want you to try to 
stand with your feet together, side by side, for about 10 seconds. Please watch 
while I demonstrate. You may use your arms, bend your knees, or move your 
body to maintain your balance, but try not to move your feet. Try to hold this 
position until I tell you to stop”. Stand next to the participant to help him or her 
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into the side-by-side position. Allow participant to hold onto your arms to get 
balance. Begin timing when participant has feet together and let go of your 
arm. If they are able to complete 10 seconds progress to semi-tandem stand. 
Repeat in semi tandem stand (heel of one foot placed by the big toe of 
the other foot). Explain “Now I want you to try to stand with the side of the 
heel of one foot touching the big toe of the other foot for about 10 seconds. 
You may put either foot in front, whichever is more comfortable for you. 
Please watch while I demonstrate”. Begin timing when participant has feet in 
position and let’s go of your arm. The test is stopped when the participant 
moves their feet, grasps the interviewer for support, or when 10 seconds has 
elapsed. Record time on Case Report Form If they are able to complete 10 
seconds progress to tandem stand. 
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Tandem Stand (feet directly in front of each other) Explain “Now I want 
you to try to stand with the heel of one foot in front of and touching the toes of 
the other foot for 10 seconds. You may put either foot in front, whichever is 
more comfortable for you. Please watch while I demonstrate”.  Stand next to 
the participant to help him or her into the side-by-side position. Allow 
participant to hold onto your arms to get balance. Begin timing when 
participant has feet together and let’s go of your arm.  
 
SCORING:  
Side-by-Side stand  
Held for 10 sec              ❒1 point  
Not held for 10 sec       ❒0 points  
Not attempted               ❒0 points 
If 0 points, end Balance Tests 
 
Semi-Tandem Stand  
Held for 10 sec              ❒1 points 
Not held for 10 sec       ❒0 points 
Not attempted               ❒0 points  
If 0 points, end Balance Tests 
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Tandem Stand  
Held for 10 sec            ❒2 point 
 Held for 3 to 9.99 sec ❒1 points 
 Held for < than 3 sec ❒0 points  
Not attempted             ❒0 points  
 
Total Balance Tests score __________ (sum points) 
 
3. GAIT SPEED: 
Mark out the distance with a tape measure and put a cone at either end. 
Place a chair at the other end if you think the participant might require it. 
Explain “This is our walking course. If you use a walking aid when walking 
outside your home, please use it for this test. I want you to walk at your usual 
pace between the two cones Walk all the way past the cone before you stop. I 
will walk behind you. We will be doing this test two times”.        
               For 4-Meter Walk:  
                     If time is more than 8.70 sec:   ❒ 1 point 
                     If time is 6.21 to 8.70 sec:       ❒ 2 points 
                     If time is 4.82 to 6.20 sec        ❒ 3 points 
                     If time is less than 4.82 sec:   ❒ 4 points  
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Scoring for SSPB 
                 Total Balance Test score _______ points  
                  Gait Speed Test score _______ points 
                 Chair Stand Test score _______ points  
                 Total Score _______ points (sum of points above) 
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MINI MENTAL STATUS EXAMINATION 
(Tamil version) 
The Mini Mental State Examination (MMSE) is a tool that can be used 
to systematically and thoroughly assess mental status. It is an 11-question 
measure that tests five areas of cognitive function: orientation, registration, 
attention and calculation, recall, and language. The maximum score is 30. A 
score of 23 or lower is indicative of cognitive impairment. 
ORIENTATION      
Time:           Year        Season        Month        Date     Time    /5 
Place:         Country        Town        District        Hospital      Floor  /5 
REGISTRATION  
 Examiner names three objects (e.g. apple, table, penny) and asks the 
patient to repeat (1 point for each correct) /3 
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ATTENTION AND CALCULATION   
Subtract 7 from 100, then repeat from result. Continue five times: 100, 
93, 86, 79, 65.           /5                                   
RECALL 
Ask for the names of the three objects learned earlier    /3  
LANGUAGE 
Name two objects (e.g. pen, watch).                                   /2 
Repeat “No ifs, ands, or buts”                                          /1  
Give a three-stage command. 
 Score 1 for each stage. (e.g. “Place index finger of right hand on your 
nose and then on your left ear”).                                                             /3  
Ask the patient to read and obey a written command on a piece of paper. 
The written instruction is: “Close your eyes”.                                    /1  
Ask the patient to write a sentence. Score 1 if it is sensible and has a 
subject and a verb.                                                   /1 
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COPYING: Ask the patient to copy a pair of intersecting pentagons /1 
TOTAL SCORE                               
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                          RESULTS 
 AGE 
Age group Frequency Percent 
60-70 Years 79 52.7 
71-80 Years 56 37.3 
Above 80 Years 15 10.0 
Total 150 100.0 
Of the 150 participants – 52.7% (n=79) were young old, 37.3% (n=56) 
old old and the  remaining 10% (n=15)  belonged to the oldest old category. 
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In this cross-sectional study, there was no significant association between HDL 
levels and age. 
Pearson Chi-Square=4.291 p=0.368 
Since results are quite variable in the literature, more prospective studies 
are recommended to better define the causes and consequences of cholesterol 
and lipoprotein changes in old age.  
 
 Age group Total 
60-70 Years 71-80 Years Above 80 
Years 
group 
<40mg/dl 
Count 27 19 4 50 
% within 
group 
54.0% 38.0% 8.0% 100.0%
40mg/dl -
49mg/dl 
Count 22 20 8 50 
% within 
group 
44.0% 40.0% 16.0% 100.0%
>49mg/dl 
Count 30 17 3 50 
% within 
group 
60.0% 34.0% 6.0% 100.0%
Total 
Count 79 56 15 150 
% within 
group 
52.7% 37.3% 10.0% 100.0%
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GENDER 
 
Gender Frequency Percent 
Male 77 51.3 
Female 73 48.7 
Total 150 100.0 
 
77 males participated in the study as against 73 females.  
Thus the sex distribution in the study was almost equal. 
 
 
 
 
 
 
52 
 
SMOKING 
 
SMOKING 
FREQUENCY PERCENT 
Non- smokers 109 72.7 
Smokers 41 27.3 
Total 150 100.0 
 
Of the 150 patients who participated in the study, the majority (72%) were 
nonsmokers (i.e) did not smoke more than 100 cigarettes in their life-time. 
 
 
 
Smoking cigarettes is associated with decreased HDL cholesterol level, 
lecithin–cholesterol acyltransferase activity and cholesteryl-ester–transfer 
protein (CETP) activity. 
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But in this study, there was no significant association found between 
HDL levels and cigarette smoking. This could be attributed to a small sample 
size with majority of the study participants being non-smokers.  
 
Pearson Chi-Square=2.887  p=0.236 
 
 
 
 
 
 SMOKING Total 
No Yes 
group 
<40mg/dl 
Count 38 12 50 
% within group 76.0% 24.0% 100.0% 
40mg/dl - 49mg/dl 
Count 32 18 50 
% within group 64.0% 36.0% 100.0% 
>49mg/dl 
Count 39 11 50 
    
% within group 78.0% 22.0% 100.0% 
Total 
Count 109 41 150 
% within group 72.7% 27.3% 100.0% 
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ALCOHOL 
 
 
 
 
 
 
 
In the study group, 42 persons (28%) consumed alcohol while the rest 108 
(72%) denied alcohol consumption.  
 
 
 
 
ALCOHOL FREQUENCY PERCENT 
No 108 72.0 
Yes 42 28.0 
Total 150 100.0 
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 ALCOHOL Total 
No Yes 
group 
<40mg/dl 
Count 43 7 50 
% within group 86.0% 14.0% 100.0% 
40mg/dl - 49mg/dl 
Count 39 11 50 
% within group 78.0% 22.0% 100.0% 
>49mg/dl 
Count 26 24 50 
% within group 52.0% 48.0% 100.0% 
Total 
Count 108 42 150 
% within group 72.0% 28.0% 100.0% 
Pearson Chi-Square=16.675** p<=0.001 
  As depicted above, a positive association is seen between alcohol 
consumption and HDL levels. 
Alcohol consumption may elevate HDL cholesterol levels by increasing 
the cellular cholesterol efflux and plasma cholesterol esterification as proved in 
several trials. 
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HYPERTENSION 
 
With increasing longetivity, the prevalence of non-communicable diseases like 
diabetes and hypertension is also increasing in the general population. Of the 
150 patients 108 (72%) were hypertensives, that is almost every one in three of 
the study group. 
 
 
 
SHTN FREQUENCY PERCENT 
Non-Hypertensives 42 28.0 
Hypertensives 108 72.0 
Total 150 100.0 
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However there was no significant association between HDL levels and 
hypertension. 
 
 SHTN Total 
No Yes 
group 
<40mg/dl 
Count 16 34 50 
% within group 32.0% 68.0% 100.0% 
40mg/dl - 49mg/dl 
Count 11 39 50 
% within group 22.0% 78.0% 100.0% 
>49mg/dl 
Count 15 35 50 
% within group 30.0% 70.0% 100.0% 
Total 
Count 42 108 150 
% within group 28.0% 72.0% 100.0% 
Pearson Chi-Square=1.389 p=0.499 
 
 
 
 
58 
 
DIABETES MELLITUS 
T2DM 
FREQUENCY PERCENT 
Non Diabetics 79 52.7 
Diabetics 71 47.3 
Total 150 100.0 
 
Nearly half of the study population (47.3%) were diabetics and were on 
oral hypoglycemic agents or insulin. 
 
 
The prevalence of diabetes mellitus in the individuals in the third tertile 
was found to be much lower than those in first and second tertiles. This 
negative association between diabetes and HDL levels was found to be 
significant. 
59 
 
 
 T2DM Total 
No Yes 
group 
<40mg/dl 
Count 15 35 50 
% within group 30.0% 70.0% 100.0% 
40mg/dl - 49mg/dl 
Count 30 20 50 
% within group 60.0% 40.0% 100.0% 
>49mg/dl 
Count 34 16 50 
% within group 68.0% 32.0% 100.0% 
Total 
Count 79 71 150 
% within group 52.7% 47.3% 100.0% 
Pearson Chi-Square=16.099** p<0.001 
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CORONARY ARTERY DISEASE 
 
 
The prevalence of coronary artery disease, which is the leading cause of death  
worldwide, was found to be 46% (i.e) 69 out of 150. 
 
 
CAD Frequency Percent 
No 81 54.0 
Yes 69 46.0 
Total 150 100.0 
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As proven from several studies, the role of HDL as a negative predictor of 
coronary events was well established. 
 CAD Total 
No Yes 
group 
<40mg/dl 
Count 12 38 50 
% within group 24.0% 76.0% 100.0% 
40mg/dl - 49mg/dl 
Count 26 24 50 
% within group 52.0% 48.0% 100.0% 
>49mg/dl 
Count 43 7 50 
% within group 86.0% 14.0% 100.0% 
Total 
Count 81 69 150 
% within group 54.0% 46.0% 100.0% 
Pearson Chi-Square=38.808** p<0.001 
 
 
62 
 
COPD/ BRONCHIAL ASTHMA 
COPD/BA FREQUENCY PERCENT 
No 125 83.3 
Yes 25 16.7 
Total 150 100.0 
 
Of the 150 participants , only 25 had obstructive airway pathology in the form 
of  either COPD or bronchial asthma. 
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HDL did not have a positive or negative influence on the airway disease. 
 
 COPDBA Total 
No Yes 
group 
<40mg/dl 
Count 42 8 50 
% within group 84.0% 16.0% 100.0% 
40mg/dl - 49mg/dl
Count 41 9 50 
% within group 82.0% 18.0% 100.0% 
>49mg/dl 
Count 42 8 50 
% within group 84.0% 16.0% 100.0% 
Total 
Count 125 25 150 
% within group 83.3% 16.7% 100.0% 
Pearson Chi-Square=0.096 p=0.953 
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CEREBROVASCULAR ACCIDENT 
CVA 
FREQUENCY PERCENT 
No 120 80.0 
Yes 30 20.0 
Total 150 100.0 
 
Of the 150 patients, 30 had suffered cerebrovascular accidents- either ischemic 
or haemorrhagic stroke in the past. This accounts to 20% of the sample size. 
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As the incidence of stroke decreases with increasing HDL, there seems to be a 
negative association between HDL levels and stroke. 
 
 CVA Total 
No Yes 
group 
<40mg/dl 
Count 32 18 50 
% within group 64.0% 36.0% 100.0% 
40mg/dl - 49mg/dl 
Count 39 11 50 
% within group 78.0% 22.0% 100.0% 
>49mg/dl 
Count 49 1 50 
% within group 98.0% 2.0% 100.0% 
Total 
Count 120 30 150 
% within group 80.0% 20.0% 100.0% 
Pearson Chi-Square=18.250** p<0.001 
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NEURODEGENERATIVE DISEASES 
Neurodegenerative 
diseases 
Frequency Percent 
No 146 97.3 
Yes 4 2.7 
Total 150 100.0 
 
The prevalence of neurodegenerative conditions like Parkinson’s disease in the 
study population was found to be 4%. 
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There was no significant association between the two parameters. 
 
 N#DISEASE Total 
No Yes 
group 
<40mg/dl 
Count 47 3 50 
% within group 94.0% 6.0% 100.0% 
40mg/dl - 49mg/dl 
Count 50 0 50 
% within group 100.0% 0.0% 100.0% 
>49mg/dl 
Count 49 1 50 
% within group 98.0% 2.0% 100.0% 
Total 
Count 146 4 150 
% within group 97.3% 2.7% 100.0% 
Pearson Chi-Square=3.596  p=0.166 
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BODY MASS INDEX (BMI)  
 
BMI_GROUP FREQUENCY PERCENT 
18.5 -24.99 107 71.3 
25-29.99 40 26.7 
30& Above 3 2.0 
Total 150 100.0 
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Of the 150 participants, 103 were normal weight, 40 were overweight and 3 
were obese.No significant association was found between HDL levels and 
BMI. 
 
 BMI_Group Total 
18.5 -
4.99 
25-
9.99 
30& 
Above 
group 
<40mg/dl 
Count 30 19 1 50 
% within group 60.0% 38.0% 2.0% 100.0% 
40mg/dl - 49mg/dl 
Count 38 11 1 50 
% within group 76.0% 22.0% 2.0% 100.0% 
>49mg/dl 
Count 39 10 1 50 
% within group 78.0% 20.0% 2.0% 100.0% 
Total 
Count 107 40 3 150 
% within group 71.3% 26.7% 2.0% 100.0% 
Pearson Chi-Square=5.014 p= 0.286 
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EFFECT OF HDL ON PHYSICAL PERFORMANCE AND COGNITION 
 
**p<0.0001 
  
 N Mean Std. 
Deviation
Std. 
Error 
95% 
Confidence 
Interval for
Mean 
MinimumMaximum 
Lower 
Bound 
Upper 
Bound 
F value 
SPPBS 
<40mg/dl 50 6.4400 1.40204 .198286.0415 6.8385 4.00 9.00 
17.481**
40mg/dl 
- 
49mg/dl 
50 7.0200 1.03982 .147056.7245 7.3155 6.00 10.00 
>49mg/dl 50 7.7800 .91003 .128707.5214 8.0386 6.00 9.00 
Total 1507.0800 1.25597 .102556.8774 7.2826 4.00 10.00 
MMSE 
<40mg/dl 50 26.10002.35822 .3335025.429826.770221.00 30.00 
28.803**
40mg/dl 
- 
49mg/dl 
50 27.84002.29783 .3249627.187028.493020.00 30.00 
>49mg/dl 50 29.18001.25666 .1777228.822929.537126.00 30.00 
Total 15027.70672.38436 .1946827.322028.091420.00 30.00 
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The mean SPPBS for persons belonging to the first, second and third 
tertiles are 6.44, 7.02, 7.78 respectively. This goes to prove that there is a 
positive association between HDL levels and physical performance (i.e) with 
increasing HDL levels the physical performance (as measured by the short 
physical performance battery) improves. This association was found to be 
statistically significant.(p<0.0001) 
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The mean MMSE scores for persons belonging to the first, second and 
third tertiles are 25.42 , 27.18 , 28.82  respectively. This goes to prove that 
there is a positive association between HDL levels and cognition (i.e) with 
increasing HDL levels the cognitive function (as measured by the short 
physical performance battery) improves. This association was found to be 
statistically significant.(p<0.0001) 
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Bonferroni 
Dependent 
Variable 
(I) group (J) group Mean 
Difference 
(I-J) 
Std. 
Error 
Sig. 95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
HDL 
<40mg/dl 
40mg/dl -
49mg/dl -10.16000
* .38351 .000 
-
11.088
7 
-9.2313 
>49mg/dl -17.18000* .38351 .000 
-
18.108
7 
-16.2513 
40mg/dl -
49mg/dl 
<40mg/dl 10.16000* .38351 .000 9.2313 11.0887 
>49mg/dl -7.02000* .38351 .000 -7.9487 -6.0913 
>49mg/dl 
<40mg/dl 17.18000* .38351 .000 16.2513 18.1087 
40mg/dl -
49mg/dl 7.02000
* .38351 .000 6.0913 7.9487 
SPPBS 
<40mg/dl 
40mg/dl -
49mg/dl -.58000
* .22731 .035 -1.1305 -.0295 
>49mg/dl -1.34000* .22731 .000 -1.8905 -.7895 
40mg/dl -
49mg/dl 
<40mg/dl .58000* .22731 .035 .0295 1.1305 
>49mg/dl -.76000* .22731 .003 -1.3105 -.2095 
>49mg/dl 
<40mg/dl 1.34000* .22731 .000 .7895 1.8905 
40mg/dl -
49mg/dl .76000
* .22731 .003 .2095 1.3105 
MMSE 
<40mg/dl 
40mg/dl -
49mg/dl -1.74000
* .40695 .000 -2.7255 -.7545 
>49mg/dl -3.08000* .40695 .000 -4.0655 -2.0945 
40mg/dl -
49mg/dl 
<40mg/dl 1.74000* .40695 .000 .7545 2.7255 
>49mg/dl -1.34000* .40695 .004 -2.3255 -.3545 
>49mg/dl 
<40mg/dl 3.08000* .40695 .000 2.0945 4.0655 
40mg/dl -
49mg/dl 1.34000
* .40695 .004 .3545 2.3255 
*. The mean difference is significant at the 0.05 level. 
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DISCUSSION 
In this study conducted at RGGGH patients presenting to the hospital 
were selected by simple random sampling and divided into three tertiles based 
on their HDL levels. The physical performance and cognitive function of the 
participants in each tertile was assessed using short physical performance 
battery and MMSE respectively. The list of co-morbidities and personal history 
of all the patients was collected. 
HDL AND CO-VARIATES  
On analyzing the collected data, a statistically significant association 
was observed between HDL levels and the following factors 
• Alcohol 
• Diabetes mellitus 
• Coronary artery disease 
• Cerebrovascular events 
 In our study, of the 150 participants 42 (28%) consumed alcohol. On 
comparison, percentage of alcohol consumers was highest in the third tertile 
and least in the first tertile. This shows that HDL levels in those who consumed 
alcohol was significantly higher than those who refrained from alcohol abuse. 
Thus there is a significant positive association between HDL levels and alcohol 
consumption. This is in accordance with several studies which have 
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demonstrated that mild to moderate consumption of alcohol rises levels of 
HDL 
Another factor having significant association with HDL levels in our 
study is diabetes. Unlike in alcohol consumption, the association between HDL 
and diabetes is a negative one (i.e) HDL acts as a negative predictor of diabetes 
mellitus. Prevalence of diabetes was found to be less in those with high HDL 
cholesterol level.( 70% in the first tertile, 40% in the second tertile and 32% in 
the third tertile).This is attributed to increased insulin sensitivity induced by 
HDL cholesterol. Similar results were obtained in the ilSIRENTE study, 
conducted in Central Italy 
The cardio protective role of HDL is well established in several trials. In 
our study too, a negative association was observed between HDL and 
prevalence of CAD. Of the 150 participants, 69 had CAD. Among the 69, 38 
persons belonged to the first tertile, 24 to the second tertile and 7 to the third 
tertile. The negative association between HDL and CAD was statistically 
significant. Hence the role of HDL as a negative predictor of coronary events 
was confirmed. 
Similarly, a negative association between HDL and CVA was observed 
among the study participants. This association can be attributed to the athero 
protective effects of HDL. 
There was no significant association between HDL levels and other 
variables like age and BMI. This is contradiction to the the ilSIRENTE study, 
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conducted in Central Italy, were a significant association was established with 
the above factors. 
Also smoking, COPD and neurodegenerative conditions like Parkinsons 
did not have any significant association with HDL. 
HDL AND PHYSICAL PERFORMANCE 
Physical performance of the study participants was assessed using the 
short physical performance battery in which  the following components was 
tested - gait speed, repeated chair stand and balance. The mean SPPBS for 
persons belonging to the first, second and third tertiles was calculated and was 
found to be 6.44, 7.02, 7.78 respectively. The data revealed a positive 
association between HDL levels and physical performance (i.e) with increasing 
HDL levels the physical performance (as measured by the short physical 
performance battery) improves. This association was found to be statistically 
significant (p<0.0001).The better physical performance in individuals with 
higher HDL can be probably attributed to the reasons discussed below. 
• Cholesterol levels may be associated inversely with the onset and 
outcomes of specific diseases (31). 
• Higher cholesterol levels have been associated with better short-
term health outcomes after acute strokes (32). 
• Another study found that cholesterol levels were related inversely 
to morbidity and mortality after surgery (33). 
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• Finally low cholesterol concentration is often associated with 
poor health status and impaired disability recovery (34). 
Hence even though genetic predisposition and specific metabolic 
conditions are the most important determinants of serum cholesterol 
concentration, reduced HDL-cholesterol levels have been hypothesized to be a 
general marker of poor wellbeing and reduced physical condition. 
HDL AND COGNITION 
Cognition in the study participants was assessed using Mini Mental 
Status Examination (MMSE) tamil version. The mean MMSE scores for 
persons belonging to the first, second and third tertiles was calculated and was 
found to be 25.42 , 27.18 , 28.82  respectively. This implies that there is a 
positive association between HDL levels and cognition (i.e) with increasing 
HDL levels the cognitive function (as measured by MMSE) improves. This 
association was found to be statistically significant.(p<0.0001). This result is in 
concordance with the studies conducted previously in Korea and China. The 
improved cognition in individuals with higher HDL levels can be attributed to 
the fact that HDL prohibits the formation of beta amyloid plaques, which 
constitutes one of the defining hallmarks of neurodegenerative diseases like 
Alzheimer's disease (35).  
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STRENGTHS AND LIMITATIONS OF THE STUDY 
STRENGTH  
9 Almost equal number of men and women were included in the study.  
9 There were equal number of study participants in all three categories of 
HDL. 
LIMITATION  
9 Small sample size. 
9 Hospital based study 
9 Hormones which are thought to have a causative role were not tested  
9  This study included patients who are on statins. 
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CONCLUSION 
  In conclusion, the present study suggests that among the elderly, higher 
levels of HDL-cholesterol are associated with better physical performance and 
cognition. This result is of particular importance as improved HDL-cholesterol 
levels by either lifestyle modification or pharmacological intervention could 
get better physical performance and cognition in the elderly.  
Also the study revealed a statistically significant association between 
HDL levels and the following factors 
• Alcohol  (positive association between HDL and alcohol consumption)  
• Diabetes mellitus  (negative association between HDL and diabetes) 
• Coronary artery disease  (negative association between HDL and 
coronary artery disease) 
• Cerebrovascular events  (negative association between HDL and 
cerebrovascular events) 
This study needs to be validated with further trials about the possible 
roles of HDL-cholesterol in the pathophysiology of ‘geriatric syndromes’ as it 
could have a phenomenal clinical implication. 
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36.  HARRISON'S PRINCIPLES OF INTERNAL MEDICINE 
37.  OXFORD TEXTBOOK OF GERIATRIC MEDICINE 
PROFORMA 
THE EFFECT OF HDL ON PHYSICAL PERFORMANCE 
AND COGNITION IN ELDERLY 
Name  Contact 
information
 
Age  
Sex  
Literacy  OP No.  
 
Smoking   Never Medical 
conditions 
Y/
N 
Duratio
n 
Past Hypertension   
Current Diabetes mellitus   
Alcoholis
m 
Never CAD   
<1 drink/week COPD/BA   
1-4 drinks/wee
k 
Old CVA   
>4 drinks/week Neurodegenerativ
e disorders 
  
 
Anthropometry 
Height  
Weight  
BMI  
 
HDL Cholesterol level  
Short physical performance battery 
score 
Gait speed 
Balance test 
Chair stand test 
MMSE score  
SHORT PHYSICAL PERFORMANCE BATTERY 
 
1 .BALANCE TESTS    
A. Side-by-Side stand   
               Held for 10 sec           ❒ 1 point 
               Not held for 10 sec   ❒ 0 points 
                     Not attempted            ❒ 0 points.  
                    If 0 points, end Balance Tests  
  
B. Semi-Tandem Stand 
                      Held for 10 sec          ❒ 1 point  
                      Not held for 10 sec   ❒ 0 points  
                      Not attempted           ❒ 0 points  
                      If 0 points, end Balance Tests  
 
C. Tandem Stand 
                   Held for 10 sec                  ❒ 2 point  
                   Held for 3 to 9.99 sec        ❒ 1 points 
                   Held for < than 3 sec         ❒ 0 points  
                    Not attempted                   ❒ 0 points   
  
 
 2. GAIT SPEED TEST  
             For 4-Meter Walk:  
                     If time is more than 8.70 sec:   ❒ 1 point 
                     If time is 6.21 to 8.70 sec:       ❒ 2 points 
                     If time is 4.82 to 6.20 sec        ❒ 3 points 
                     If time is less than 4.82 sec:   ❒ 4 points  
3. CHAIR STAND TEST   
                Participant unable to complete 5 chair stands  
                                       or completes stands in >60sec:            ❒ 0 points                                 
                If chair stand time is 16.70 sec or more:                    ❒ 1 point 
                If chair stand time is 13.70 to 16.69 sec or more:      ❒ 2 points  
                If chair stand time is 11.20 to 13.69 sec:                    ❒ 3 points 
                If chair stand time is 11.19 sec or less:                       ❒ 4 points 
  TOTAL SCORE:          
MINI MENTAL STATUS EXAMINATION                                 
ORIENTATION      
Time:           Year        Season        Month        Date     Time                        /5 
Place:         Country        Town        District        Hospital      Floor             /5 
REGISTRATION  
 Examiner names three objects (e.g. apple, table, penny) and asks the patient to 
repeat (1 point for each correct)                       
/3 
ATTENTION AND CALCULATION   
 Subtract 7 from 100, then repeat from result. Continue five times: 100, 93, 86, 
79, 65.       /5                                                                                                             
RECALL 
 Ask for the names of the three objects learned earlier                           /3  
LANGUAGE 
Name two objects (e.g. pen, watch).                                                            /2 
Repeat “No ifs, ands, or buts”                                                                        /1  
Give a three-stage command. 
 Score 1 for each stage. (e.g. “Place index finger of right hand on your nose and 
then on your left ear”).                       
/3  
Ask the patient to read and obey a written command on a piece of paper. The 
written instruction is: “Close your eyes”.                       
/1  
Ask the patient to write a sentence. Score 1 if it is sensible and has a subject 
and a verb.                                                                                                    
                                                                                                     /1 
COPYING: Ask the patient to copy a pair of intersecting pentagons      /1 
  TOTAL SCORE                                                                  
INFORMATION SHEET  
 We are conducting a study titled “Effect of HDL on Physical Performance and 
Cognition in Elderly” among patients attending Geriatric OPD at Rajiv Gandhi 
Government General Hospital, Chennai .  
  
 We are selecting certain cases and if you are found eligible, we may be using your 
blood samples to do lipid profile, we will collect your clinical history and will conduct 
simple office based tests to assess your physical performance and cognition.  
  
 The privacy of the patients in the research will be maintained throughout the study. In 
the event of any publication or presentation resulting from the research, no personally 
identifiable information will be shared.  
  
 Taking part in this study is voluntary. You are free to decide whether to participate in 
this study or to withdraw at any time; your decision will not result in any loss of 
benefits to which you are otherwise entitled.  
  
 The results of the special study may be intimated to you at the end of the study period 
or during the study if anything is found abnormal which may aid in the management 
or treatment.  
  
Signature of investigator         Signature of participant  
  
Date:   
Place: Chennai.  
                                                      PATIENT CONSENT FORM   
    
Study Detail   
                                                 
    :  Effect of HDL on Physical Performance and Cognition  
Study Centre       : Rajiv Gandhi Govt. General Hospital, Chennai. 
   
Patient’s Name       :  
Patient’s Age        :   
 
OP. No.                                    : 
 Patient may check (9) these boxes:   
a) I confirm that I have understood the purpose of procedure for the above study. I have the 
opportunity to ask question and all my questions and doubts have been answered to my 
complete satisfaction.  
b) I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being affected.  
c) I understand that sponsor of the clinical study, others working on the sponsor’s behalf, 
the ethical committee and the regulatory authorities will not need my permission to look at 
my health records, both in respect of current study and any further research that may be 
conducted in relation to it, even if I withdraw from the study I agree to this access. However, 
I understand that my identity will not be revealed in any information released to third parties 
or published, unless as required under the law. I agree not to restrict the use of any data or 
results that arise from this study.  
d) I agree to take part in the above study and to comply with the instructions given during 
the study and faithfully cooperate with the study team and to immediately inform the study staff if 
I suffer from any deterioration in my health or wellbeing or any unexpected or unusual symptoms.  
e) I hereby consent to participate in this study.  
f) I hereby give permission to undergo clinical examination and biochemical tests.  
  
  
  
  

  
Signature / Thumb Impression      Signature of Investigator  
  
  
  
Patient’s Name & Address:        
                                                                           Dr.OVIYA ELANGO 
  
Urkund Analysis Result  
Analysed Document: New final doc.doc (D42480530) 
Submitted: 10/12/2018 2:28:00 PM  
Submitted By: oviyase@gmail.com 
Significance: 2 %  
Sources included in the report:  
http://jultika.oulu.fi/Record/isbn951-42-7866-6 
https://helda.helsinki.fi/handle/10138/22130 
https://helda.helsinki.fi/handle/10138/22765 
https://helda.helsinki.fi/handle/10138/22636 http://jultika.oulu.fi/Record/nbnfi-
fe201704116050 https://openarchive.ki.se/xmlui/handle/10616/45179 
https://www.ncbi.nlm.nih.gov/pubmed/19349317 Instances where selected 
sources appear: 12  
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MASTER CHART 
NAME  AGE  SEX 
EDUCATIO
N 
SMOK
ING 
ALC
OH
OL  SHN  T2M  CAD 
COPD 
/BA  CVA 
N.DI
SEA
SE  BMI 
H
DL 
SPPB
S 
MM
SE 
ABDUL  67  M 
UNEDUCA
TED  Y  N  Y  N  N  N  N  N  21.2  45  7  30 
ADHILAKSHMI  66  F 
UNEDUCA
TED  N  Y  Y  N  Y  N  Y  N  22  32  7  26 
AKHILANDESWARI  66  F  5TH STD  N  N  Y  N  N  N  Y  N  25.8  44  6  30 
AMAVASAI  68  F 
UNEDUCA
TED  N  Y  N  Y  N  N  N  N  21.9  52  9  30 
ANAND  66  M  10TH STD  N  N  Y  N  N  N  N  N  21.3  50  9  30 
ANBARASAN  65  M  12TH STD  Y  Y  Y  N  N  Y  N  N  21.2  53  8  30 
ANGAMMA  66  F 
UNEDUCA
TED  N  N  N  N  N  Y  N  N  26  55  9  30 
ANTHONIAMMAL  63  F  8TH STD  N  N  Y  Y  Y  N  N  N  26.5  44  6  30 
AROKIYARAJ  65  M 
UNEDUCA
TED  Y  N  N  N  N  Y  Y  N  26  38  9  26 
BABU  82  M 
UNEDUCA
TED  N  N  Y  N  Y  N  Y  N  21  33  5  24 
BALAMURUGA  68  M  8TH STD  Y  N  Y  N  N  N  N  N  21.1  42  7  29 
BALAMURUGAN  68  M  12TH STD  N  N  Y  N  Y  N  N  N  25.5  35  9  30 
BALU  78  M 
UNEDUCA
TED  N  N  Y  N  N  N  N  N  25.8  45  6  28 
BARATHI  68  F 
UNEDUCA
TED  N  N  Y  Y  Y  N  N  N  18.8  37  8  27 
BASKAR  72  M 
UNEDUCA
TED  N  Y  N  Y  N  N  N  N  21.8  52  7  30 
BHAKIYAM  68  F 
UNEDUCA
TED  N  Y  Y  N  N  N  N  N  23.4  53  8  30 
BHUVANESHWARI  68  F  4THSTD  N  N  Y  N  N  N  N  N  22.8  53  8  29 
CHANDRA  65  F  4TH STD  N  N  Y  N  N  N  N  N  21.8  51  8  30 
CHINNADURAI  83  M 
UNEDUCA
TED  Y  N  Y  N  Y  N  Y  N  22.8  44  6  25 
CHITRADEVI  73  F 
UNEDUCA
TED  N  N  Y  Y  N  N  N  N  22.8  48  6  24 
DANAPAL  70  M 
UNEDUCA
TED  Y  Y  Y  N  Y  N  N  N  25.2  52  7  29 
DAVID  71  M  10TH STD  N  N  N  Y  N  N  N  N  22.8  53  7  30 
DHANALAKSHMI  80  F 
UNEDUCA
TED  N  N  Y  Y  N  N  N  N  22.1  53  7  29 
DHARMALINGAM  83  M 
UNEDUCA
TED  N  Y  N  Y  Y  N  N  N  26  34  6  26 
DINAKAR  67  M  7TH STD  N  Y  N  N  N  N  N  Y  24.2  51  6  30 
DURAIRAJ  73  M  5TH STD  Y  N  Y  N  Y  Y  N  N  24  32  7  26 
EHWARIAMAL  61  F 
UNEDUCA
TED  N  N  Y  N  N  N  N  N  24.5  49  7  30 
ELANGO  69  M  10TH STD  N  Y  Y  N  N  N  N  N  25.2  51  9  30 
ELAVARASAN  73  M 
UNEDUCA
TED  Y  N  Y  N  N  N  N  N  21.7  54  7  29 
ESHWARI  69  F  5TH STD  N  N  Y  Y  N  N  N  N  27  34  7  23 
EZHIL  61  M  B.A  Y  Y  N  N  N  Y  N  N  25.8  53  9  30 
GANESAN  68  M  12TH STD  N  N  Y  N  N  N  N  N  21.8  51  8  30 
GOPAL  61  M  12TH STD  N  Y  N  Y  Y  N  Y  N  22  35  8  27 
GUNASEKARAN  71  M 
UNEDUCA
TED  N  Y  Y  Y  Y  N  Y  N  22.7  45  7  22 
GUNASEKARAN  78  M 
UNEDUCA
TED  Y  Y  N  Y  N  Y  N  N  21.1  53  7  27 
HARIDOSS  65  M  B.A  Y  Y  Y  Y  N  N  N  N  22.5  52  9  30 
JANAKI  66  F 
UNEDUCA
TED  N  N  Y  Y  N  N  N  N  21.8  53  8  30 
JESURATHINAM  81  M 
UNEDUCA
TED  N  N  Y  Y  Y  N  N  N  21.21  44  6  26 
JOHN  77  M  12THSTD  N  Y  Y  Y  Y  N  N  N  21.4  33  8  29 
JOSEPH  68  M  6TH STD  Y  Y  Y  N  Y  Y  N  N  24.8  43  7  30 
KALAISELVI  66  F  5TH STD  N  N  Y  N  N  N  N  N  24  52  9  30 
KALIDOSS  77  M  10TH STD  N  N  Y  N  N  N  N  N  21.7  51  7  30 
KALPANA  79  F 
UNEDUCA
TED  N  N  Y  N  Y  N  N  N  24.7  46  6  26 
KAMATCHI  60  F  7TH STD  N  N  N  N  N  Y  N  N  28  39  6  23 
KANAKAVALLI  74  F 
UNEDUCA
TED  N  N  N  N  Y  N  Y  N  23.9  48  7  28 
KANAMMA  72  F 
UNEDUCA
TED  N  N  Y  Y  Y  N  N  N  23.18  44  6  28 
KANAMMAL  72  F 
UNEDUCA
TED  N  N  Y  N  N  Y  N  N  21.9  47  6  28 
KANAPPAN  74  M  7TH STD  N  Y  N  N  Y  N  N  N  22.5  53  8  30 
KAVIARASAN  69  M  8TH STD  Y  N  Y  Y  N  N  N  N  23.1  51  8  30 
KESAVAN  62  M  B.A  N  Y  N  Y  N  N  N  N  22.8  52  9  30 
KRISHNAMMAL  72  F 
UNEDUCA
TED  N  N  Y  N  Y  N  Y  N  26.6  37  7  29 
KRISHNAMOORTHY  72  M  12TH STD  N  N  N  Y  N  N  Y  N  22.6  32  6  28 
KRISHNAN  74  M 
UNEDUCA
TED  N  N  N  Y  N  N  N  Y  20.4  33  4  23 
KUMAR  78  M 
UNEDUCA
TED  Y  N  Y  N  N  N  Y  Y  28.8  34  5  21 
KUMAR  71  M  5TH STD  N  N  N  Y  Y  N  Y  N  22.9  41  6  29 
KUMARAVEL  75  M 
UNEDUCA
TED  Y  Y  Y  N  N  N  N  N  22.9  50  9  30 
KUPPUSAMY  82  M 
UNEDUCA
TED  N  N  Y  N  Y  N  N  N  21.9  42  6  26 
KUTTIAMMAL  70  F 
UNEDUCA
TED  N  Y  Y  N  N  N  N  N  19.8  54  7  27 
LAKSHMI  63  F 
UNEDUCA
TED  N  N  Y  Y  Y  N  N  N  27  38  6  24 
LATHA  64  F  5TH STD  N  N  Y  N  Y  N  N  N  26.5  48  7  30 
LOORTHMARY  68  F  10TH  STD  N  N  Y  N  Y  N  N  N  25.8  48  6  30 
MALAR  76  F 
UNEDUCA
TED  N  N  Y  N  N  N  N  N  21.3  53  8  29 
MALLIGA  60  F  7TH STD  N  N  Y  N  Y  N  N  N  23.4  53  8  30 
MANICKAM  66  M  5TH STD  N  N  N  Y  Y  N  Y  N  23.6  30  5  27 
MANICKAM  74  M 
UNEDUCA
TED  Y  Y  Y  Y  N  Y  N  N  19  31  6  27 
MANICKAM  84  M 
UNEDUCA
TED  Y  Y  Y  N  N  Y  N  N  26.5  44  6  26 
MANJULA  68  F  4TH STD  N  N  Y  N  N  N  N  N  22.1  51  8  30 
MARY  73  F  2ND STD  N  N  Y  N  Y  N  Y  N  24.6  35  5  23 
MASILAMANI  77  M 
UNEDUCA
TED  Y  Y  Y  N  N  Y  N  N  25.6  45  6  26 
MEENATCHI  71  F 
UNEDUCA
TED  N  N  Y  N  Y  Y  N  N  20  36  7  26 
MEERA  70  F 
UNEDUCA
TED  N  N  Y  Y  Y  N  N  N  26  38  8  28 
MOHAMAD  76  M  3RD STD  Y  Y  Y  N  Y  N  N  N  20.6  44  7  30 
MOHANA  76  F 
UNEDUCA
TED  N  N  Y  Y  Y  N  N  N  21.5  46  6  28 
MURUGAN  64  M  10TH  STD  Y  N  Y  N  N  N  N  N  22.9  46  7  28 
MURUGAN  65  M 
UNEDUCA
TED  N  N  Y  N  N  N  N  N  23.8  50  7  29 
MUTHUKUMARI  71  F 
UNEDUCA
TED  N  N  N  Y  N  N  N  N  26.5  48  7  28 
NAGAMMAL  82  F 
UNEDUCA
TED  N  N  Y  Y  Y  N  N  N  19.2  52  6  27 
NARAYANAN  64  M  7TH STD  N  Y  Y  Y  N  Y  Y  N  26.9  33  6  27 
NATESAN  73  M  10TH STD  N  N  N  N  N  N  N  N  22.4  55  9  30 
PACHAIYAMMAL  72  F 
UNEDUCA
TED  N  N  N  Y  Y  N  N  N  26.1  37  6  26 
PADMANABAN  77  M  9TH STD  Y  N  Y  N  N  N  N  N  24.8  45  7  28 
PADMAVATHY  61  F  8TH STD  N  N  N  N  Y  N  N  N  20  36  6  25 
PALPANDI  80  M 
UNEDUCA
TED  Y  Y  Y  Y  Y  N  N  N  20.7  42  5  27 
PANDU  66  M 
UNEDUCA
TED  Y  Y  Y  Y  Y  N  N  N  24.8  33  6  24 
PARVATHY  73  F 
UNEDUCA
TED  N  N  Y  Y  Y  N  N  N  24.9  45  6  26 
PATTAMAL  69  F  3RD STD  N  N  Y  N  N  N  Y  N  24.8  45  7  28 
PITCHAIAMMAL  66  F 
UNEDUCA
TED  N  N  Y  N  Y  N  Y  N  21  37  5  25 
PONAMMAL  88  F 
UNEDUCA
TED  N  N  N  N  Y  N  N  N  23.2  45  6  26 
PONAPPAN  81  M 
UNEDUCA
TED  N  N  N  N  Y  N  N  N  22.3  51  8  27 
PONNI  80  F 
UNEDUCA
TED  N  N  Y  N  N  N  N  N  19.2  50  7  27 
PONNUDURAI  86  M 
UNEDUCA
TED  Y  Y  Y  N  Y  Y  Y  N  23  50  6  26 
PONUTHAI  77  F 
UNEDUCA
TED  N  N  Y  Y  Y  Y  N  N  23.9  45  6  27 
POONGOTHAI  69  F  6TH STD  N  N  Y  Y  N  N  N  N  22.2  53  8  30 
PUSHPAVALLI  86  F 
UNEDUCA
TED  N  N  Y  Y  Y  N  Y  N  25.1  45  7  26 
RAANI  66  F  6TH STD  N  N  Y  Y  N  N  N  N  22.4  51  9  30 
RAJAMMAL  61  F 
UNEDUCA
TED  N  N  Y  Y  Y  N  Y  N  19  36  9  26 
RAJASEKAR  71  M  10TH STD  Y  Y  Y  N  N  Y  N  N  21.8  53  7  30 
RAJATHI  69  F 
UNEDUCA
TED  N  N  Y  Y  N  N  N  N  26.5  38  8  26 
RAJATHI  68  F 
UNEDUCA
TED  N  N  N  N  Y  Y  N  N  24.5  46  7  27 
RAJENDRAN  62  M  12TH STD  Y  Y  Y  Y  N  N  N  N  25.1  44  8  30 
RAJESWARI  72  F 
UNEDUCA
TED  N  N  Y  Y  Y  N  Y  N  21.8  36  7  27 
RAM MOHAN  74  M  7TH STD  N  N  N  N  N  N  N  N  25  53  7  30 
RAMAMOORTHY  60  M  10TH STD  Y  N  Y  Y  N  N  N  N  24.9  37  6  30 
RAMANI  74  M 
UNEDUCA
TED  Y  Y  Y  Y  Y  N  N  N  22.5  38  8  23 
RAMUTHAI  79  F 
UNEDUCA
TED  N  N  N  N  N  Y  N  N  22.6  47  7  27 
RAVINDRAN  79  M  7TH STD  Y  N  Y  N  N  N  Y  N  26.1  45  6  30 
RENUKA  70  F 
UNEDUCA
TED  N  N  Y  Y  N  N  N  N  22  52  6  27 
REVATHY  66  F  6TH STD  N  N  Y  N  N  N  N  N  20  52  8  30 
SANTHANAM  66  M  7TH STD  N  N  Y  N  N  N  N  N  26.1  53  9  27 
SARASWATHY  72  F 
UNEDUCA
TED  N  N  Y  Y  Y  N  Y  N  20  35  5  24 
SARATHAMAL  67  F 
UNEDUCA
TED  N  N  N  Y  Y  N  N  N  27  37  6  26 
SARATHY  67  M  7TH STD  N  Y  N  Y  N  N  N  N  19.8  46  8  20 
SAROJA  86  F 
UNEDUCA
TED  N  N  N  Y  N  N  N  N  26  36  8  30 
SAVITHRI  68  F 
UNEDUCA
TED  N  N  Y  Y  Y  N  N  N  21.4  38  7  27 
SEETHA  77  F 
UNEDUCA
TED  N  N  Y  Y  Y  N  Y  N  33.9  45  7  27 
SEETHALAKSHMI  80  F 
UNEDUCA
TED  N  N  N  N  N  Y  N  N  25  54  7  29 
SELVAMUTHU  70  M 
UNEDUCA
TED  Y  N  Y  N  Y  N  N  N  24.8  34  9  28 
SELVARAJ  76  M 
UNEDUCA
TED  Y  Y  N  Y  Y  Y  y  N  22.9  30  4  26 
SELVI  81  F 
UNEDUCA
TED  N  Y  Y  N  N  N  Y  N  22.8  46  7  26 
SELVI  70  F 
UNEDUCA
TED  N  N  N  Y  N  N  N  N  24.5  51  8  29 
SENTHIL  61  M  B.Sc  Y  Y  Y  N  N  N  N  N  25  53  8  30 
SIVAKAMI  81  F 
UNEDUCA
TED  N  N  N  Y  Y  N  N  N  30  36  8  27 
SIVAKUMAR  76  M  4TH STD  N  Y  Y  N  Y  N  N  N  27  36  8  28 
SRINIVASAN  82  M 
UNEDUCA
TED  Y  N  N  Y  Y  N  N  N  23.9  46  6  24 
SUBAIYA  65  M  12TH STD  N  N  Y  Y  Y  N  N  N  26.9  36  10  30 
SUBASH  68  M  N  N  Y  N  Y  N  N  N  N  19.2  36  4  26 
SUBRAMANI  72  M 
UNEDUCA
TED  Y  Y  Y  Y  Y  N  Y  Y  26.6  32  5  22 
SUBRAMANI  64  M  12TH STD  N  N  N  Y  Y  N  N  N  19.9  43  8  30 
SUBRAMANIAN  70  M  12TH STD  N  N  Y  N  N  N  N  N  34.1  54  8  30 
SUNDARI  65  F  3RD STD  N  N  Y  Y  N  N  N  N  23.7  46  7  30 
SURESH  66  M  10TH  STD  Y  Y  N  N  N  N  N  N  21.65  43  7  30 
THAMARAI  66  F 
UNEDUCA
TED  N  N  Y  N  N  N  N  N  26.1  53  8  29 
THANGAPANDIYAN  76  M 
UNEDUCA
TED  Y  N  Y  N  N  N  Y  N  23.5  44  7  28 
THENDRAL  70  F 
UNEDUCA
TED  N  N  N  Y  N  Y  N  N  26.5  50  7  26 
THENMOZHI  71  F 
UNEDUCA
TED  N  N  Y  N  N  N  N  N  23  51  8  30 
THYAGARAJAN  72  M 
UNEDUCA
TED  N  Y  Y  N  N  N  N  N  19.5  53  7  28 
VADIVEL  66  M 
UNEDUCA
TED  Y  Y  N  N  Y  N  N  N  21  32  6  24 
VALLI  80  F 
UNEDUCA
TED  N  N  Y  Y  Y  N  N  N  19  37  6  24 
VALLIAMAL  78  F 
UNEDUCA
TED  N  N  Y  Y  Y  N  N  N  19.4  53  7  28 
VEERAMANI  80  M 
UNEDUCA
TED  N  N  Y  Y  Y  N  Y  N  24  31  4  21 
VEERAMMAL  64  F  5TH STD  N  N  Y  Y  Y  N  N  N  22  33  5  26 
VEERAPANDI  64  M  10TH  STD  Y  N  N  Y  N  Y  N  N  20.1  42  7  30 
VENI  64  F 
UNEDUCA
TED  N  N  Y  Y  Y  N  N  N  26.8  35  7  27 
VENKETESAN  73  M  4TH STD  Y  Y  Y  N  N  N  N  N  23.9  44  7  30 
VENKIAH  63  M  10TH STD  Y  N  Y  N  Y  N  N  N  24.4  45  8  30 
VENTESAN  69  M 
UNEDUCA
TED  Y  N  Y  Y  Y  N  N  N  19.9  35  10  28 
VIJAYA  66  F  4TH STD  N  N  Y  N  N  N  Y  N  24.2  46  6  30 
VIJAYANTHI  60  F  5TH STD  N  N  Y  Y  Y  Y  N  N  24.21  46  6  30 
VIOLET MARY  62  F  8TH STD  N  N  Y  Y  Y  Y  N  N  26.8  36  6  30 
 
 
 
